Document is current
Any future updates will be listed below
-
Authors
Tang, Colin P.
Clark, Owen
Ferrarone, John R.
Campos, Carl
Lalani, Alshad S.
Chodera, John D.
Intlekofer, Andrew M. https://orcid.org/0000-0001-9046-6549
Elemento, Olivier https://orcid.org/0000-0002-8061-9617
Mellinghoff, Ingo K. https://orcid.org/0000-0002-4347-8149
- License Information
-
More Information
Article History
Received: 15 June 2021
Accepted: 28 October 2021
First Online: 23 December 2021
Competing interests
: I.K.M. has received research funding from General Electric, Agios and Lilly and has served in advisory roles for Agios, Amgen, Debiopharm, Novartis, Puma Biotechnology, Servier Pharmaceuticals, and Voyager Therapeutics. O.E. is supported by research grants from Janssen, Johnson and Johnson, Volastra, AstraZeneca and Eli Lilly. O.E. is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and One Three Biotech. A.S.L. is an employee and shareholder of Puma Biotechnology, Inc. J.D.C. has received research funding from the Parker Institute for Cancer Immunotherapy, Relay Therapeutics, Entasis Therapeutics, Silicon Therapeutics, EMD Serono (Merck KGaA), AstraZeneca, Vir Biotechnology, Bayer, XtalPi, Foresite Laboratories, the Molecular Sciences Software Institute, the Starr Cancer Consortium, the Open Force Field Consortium and Cycle for Survival. J.D.C. is a scientific advisor and equity holder in Interline Therapeutics and Redesign Science and a current member of the Scientific Advisory Board of OpenEye Scientific Software. A complete funding history for the Chodera lab can be found at . The other authors declare no competing interests.
